[1]Zeng XF, Zhu SL, Tan ACh, et al. Disease burden and quality of life of rheumatoid arthritis in China:a systematic review[J]. Chinese Journal of Evidence-Based Medicine, 2013, 13(3):300-307.(in Chinese)
曾小峰, 朱松林, 谭爱春, 等. 我国类风湿关节炎疾病负担和生存质量研究的系统评价[J]. 中国循证医学杂志, 2013, 13(3):300-307.
[2]Broecker-Preuss M, Müller S, Britten M, et al. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status[J]. Bmc Cancer, 2014, 15(1):1-13.
[3]Kalathil SG, Lugade AA, Miller A, et al. PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy[J]. JCI Insight, 2016, 1(11):e86182.
[4]Cabrera R, Ararat M, Xu Y, et al. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2013, 62(4):737-746.
[5]Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
[6]Chen J, Jin R, Zhao J, et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma[J]. Cancer Lett, 2015, 367(1):1-11.
[7]Zhang XM, Chen FH, Huang XY, et al. Culture and identification of fibroblast-like synoviocytes from rat with adjuvant arthritis in vitro[J]. Chinese Journal of Anatomy, 2007, 30(6):770-773.(in Chinese)
张晓明, 陈飞虎, 黄学应, 等. 佐剂性关节炎大鼠成纤维样滑膜细胞的体外培养与鉴定[J]. 解剖学杂志, 2007, 30(6):770-773.
[8]Yang Y. Methotrexate in the treatment of rheumatoid arthritis[J]. Tianjin Pharmacy, 2009, 21(4):58-61.(in Chinese)
杨媛. 甲氨蝶呤在治疗类风湿性关节炎的应用[J]. 天津药学, 2009, 21(4):58-61.
[9]Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling[J]. Mol Cancer Ther, 2008, 7(10):3129-3140.
[10]Yan W, Gao J, Di Z, et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis[J]. J Hepatol, 2010, 53(1):132-144.
[11]Zahavi T, Lanton T, Divon MS, et al. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model[J]. Oncotarget, 2015, 7(4):4860-4870.
[12]Ren GH, Huang W, Xiao X, et al. Effects of oxymatrine on joint inflammation and T cell subsets in rats with collagen induced arthritis[J]. Chinese Pharmaceutical Journal, 2012, 47(5):350-353.(in Chinese)
任广慧, 黄伟, 肖旭, 等. 氧化苦参碱对胶原蛋白诱导大鼠关节炎症及T细胞亚群的影响[J]. 中国药学杂志, 2012, 47(5):350-353.
[13]Zhang Y, Lü Y, Lü TT, et al. Elevated circulating Th17 and follicular helper CD4+ T cells in patients with rheumatoid arthritis[J]. Apmis, 2015, 123(8):659-666.
[14]Bai ST, Chen PH, Chen YY, et al. Ethyl acetate extract from celastrus aculeatus Merr. Suppresses synovial inflammation in adjuvant arthritis rats through apoptosis induction of CD4(+)CD25(+)FOXP3(+) T Cells[J]. Evid Based Complement Alternat Med, 2014, 2014:460136.
[15]Lin XD, Qi YL, Chen ShQ, et al. Clinical significance of thrombospondin-4 expression in gastric carcinoma[J]. Acta Anatomica Sinica, 2010, 41(1):65-69.(in Chinese)
林贤东, 齐元麟, 陈淑勤, 等. 血小板反应素-4在胃癌中的表达及其临床意义[J]. 解剖学报, 2010, 41(1):65-69.
[16]Huang XY, Zhang XM, Chen FH, et al. Anti-proliferative effect of recombinant human endostatin on synovial fibroblasts in rats with adjuvant arthritis[J]. Eur J Pharmacol, 2014, 723(1):7-14.
[17]Fournier C. Where do T cells stand in rheumatoid arthritis [J]? Joint Bone Spine, 2005, 72(6):527-532.
[18]Roberts CA, Dickinson AK, Taams LS. The Interplay between monocytes/macrophages and CD4(+) T cell subsets in rheumatoid arthritis[J]. Front Immunol, 2015, 6(3):571-590.[19]Guo M, An G, Feng GY, et al. The research development of CD4+T cell subset in rheumatoid arthritis[J]. Chinese Journal of Cellular and Molecular Immunology, 2014, 30(9):1004-1007.(in Chinese)
郭明, 安高, 封桂英, 等. CD4+T细胞亚群在类风湿性关节炎中的研究进展[J]. 细胞与分子免疫学杂志, 2014, 30(9):1004-1007.
[20]Scrivo R, Di Franco M, Spadaro A, et al. The immunology of rheumatoid arthritis[J]. Ann N Y Acad Sci, 2007, 1108(1):312-322.
[21]Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis[J]. Clin Exp Rheumatol, 2007, 25(5 Suppl 46):S4-11.
[22]Ma L, Simpson E, Li J, et al. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia[J]. Blood, 2015, 126(2):247-256.
[23]Jung YO, Min SY, Cho ML, et al. CD8alpha+ dendritic cells enhance the antigen-specific CD4+ T-cell response and accelerate development of collagen-induced arthritis[J]. Immunol Lett, 2007, 111(2):76-83.
[24]Cho YG, Cho ML, Min SY, et al. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis[J]. Autoimmun Rev, 2007, 7(7):65-70.
[25]Koch AE. The role of angiogenesis in rheumatoid arthritis: recent developments[J]. Ann Rheum Dis, 2000, 59(Suppl 1):i65-i71.
[26]Elshabrawy HA, Chen Z, Volin MV, et al. The pathogenic role of angiogenesis in rheumatoid arthritis[J]. Angiogenesis, 2015, 18(4):433-448.
|